Overview
What is Foundation Fighting Blindness Retinal Degeneration Fund?
The Foundation Fighting Blindness Retinal Degeneration Fund is a charitable organization situated in Columbia, Maryland. Its primary mission is to expedite the transition of retinal research conducted in laboratories to clinical trials, thereby accelerating the commercialization of therapeutic solutions for individuals affected by retinal degenerative diseases. During Fiscal 2023, the organization made significant investments in Opus Genetics, Perceive Bio, and Amber Bio, three companies focusing on promising therapies for retinal degenerative conditions. Specifically, the Fund invested an additional $7 million in Opus Genetics, supporting its pipeline of orphan inherited retinal diseases such as LCA5, BEST1, RDH12, and MERTK. Additionally, they invested in Perceive Bio's clinical-stage complement factor H gene therapy program for the treatment of dry AMD and an early-stage dual leucine kinase-dependent inhibitor program for axonal neuroprotection in glaucoma and retinal diseases. Lastly, the Fund invested $1.8 million in Amber Bio to support the development of an RNA editing platform, initially intended for retinal degenerative diseases. In total, the Foundation Fighting Blindness Retinal Degeneration Fund employs a team of 10 individuals in its mission to combat retinal degenerative diseases.
Official website here: www.retinaldegenerationfund.org
Is Foundation Fighting Blindness Retinal Degeneration Fund legitimate?
Foundation Fighting Blindness Retinal Degeneration Fund is a legitimate nonprofit organization registered as a 501(c)(3) entity. Foundation Fighting Blindness Retinal Degeneration Fund submitted a form 990, which is a tax form used by tax-exempt organizations in the U.S., indicating its operational transparency and adherence to regulatory requirements. Donations to this organization are tax deductible.
Heare are some key statistics you may want to consider:
Executive Compensation: $674,390
Professional Fundraising Fees: $0
Other Salaries and Wages: $28,027
For more financial information, click here
Official website here: www.retinaldegenerationfund.org
What is the mission statement of Foundation Fighting Blindness Retinal Degeneration Fund?
The Foundation Fighting Blindness Retinal Degeneration Fund's mission is centered around accelerating the translation of laboratory-based retinal research into clinical trials. This process is aimed at expediting the commercialization of patient therapies for retinal degenerative diseases. The organization's primary focus is on investing in clinical-stage gene therapy companies, such as Opus Genetics and Perceive Bio, as well as preclinical stage companies like Amber Bio. These investments are made to advance promising therapies for various retinal degenerative diseases. For instance, in Fiscal 2023, the Foundation invested an additional $7 million in Opus Genetics to support its pipeline of orphan inherited retinal disease indications, including LCA5, BEST1, RDH12, and MERTK. Similarly, investments were made in Perceive Bio and Amber Bio to advance their respective clinical-stage and preclinical stage programs.
Official website here: www.retinaldegenerationfund.org
Who is the CEO of Foundation Fighting Blindness Retinal Degeneration Fund?
Russell W Kelley is the Managing Director, Rd Fund of Foundation Fighting Blindness Retinal Degeneration Fund. The CEO's salary of Foundation Fighting Blindness Retinal Degeneration Fund is $91,780 and their total compensation is $523,027.
Official website here: www.retinaldegenerationfund.org
What is the revenue of Foundation Fighting Blindness Retinal Degeneration Fund?
Foundation Fighting Blindness Retinal Degeneration Fund's revenue in 2023 was $9,316,837.
Official website here: www.retinaldegenerationfund.org
Who are the executives of Foundation Fighting Blindness Retinal Degeneration Fund and what are their salaries?
The average compensation at Foundation Fighting Blindness Retinal Degeneration Fund during 2023 was $70,242. There are 10 employees and 11 volunteers at Foundation Fighting Blindness Retinal Degeneration Fund.
Here are 15 key members and their salaries (Foundation Fighting Blindness Retinal Degeneration Fund's CEO's salary is $91,780 and their total compensation is $523,027):
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $15,000
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $75,000
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $0
- Other: $0
- Compensation: $0
- Related: $15,000
- Other: $0
- Compensation: $133,821
- Related: $445,893
- Other: $42,458
- Compensation: $91,780
- Related: $367,118
- Other: $64,129
- Compensation: $66,023
- Related: $264,095
- Other: $59,015
- Compensation: $280,543
- Related: $0
- Other: $59,290
Official website here: www.retinaldegenerationfund.org
Where can I find the form 990 for Foundation Fighting Blindness Retinal Degeneration Fund?
Foundation Fighting Blindness Retinal Degeneration Fund's most recent form 990 was submitted in 2023 and can be accessed here.
Official website here: www.retinaldegenerationfund.org
Learn more at the official website: www.retinaldegenerationfund.org
Mission Statement of Foundation Fighting Blindness Retinal Degeneration Fund
The Foundation Fighting Blindness Retinal Degeneration Fund is committed to accelerating the translation of retinal laboratory-based research into clinical trials, with the ultimate goal of expediting the commercialization of patient therapies for retinal degenerative diseases. This nonprofit organization focuses on three main areas, as indicated by its expenditures: investing in companies that are clinically staged, such as Opus Genetics and Perceive Bio, as well as supporting preclinical stage companies, like Amber Bio. The investments made by the Foundation Fighting Blindness Retinal Degeneration Fund are aimed at advancing promising therapies for various retinal degenerative diseases, including LCA5, BEST1, RDH12, and MERTK for Opus Genetics, and Dry AMD for Perceive Bio. The investment in Amber Bio is intended to support the development of an RNA editing platform, which will initially be applied to retinal degenerative diseases.
Shop smarter and support your favorite cause with the Give Freely browser extension. Save money with coupons and donate to charity with a single click. Download now!
Impact
October, 2024
The Foundation Fighting Blindness Retinal Degeneration Fund has significantly impacted the field of retinal research and therapy commercialization. With a mission to accelerate the translation of retinal laboratory-based research into clinical trials, the fund focuses on fostering innovative treatments for retinal degenerative diseases.
In fiscal 2023, the fund made substantial equity investments totaling over $11 million in three promising biotech companies: Opus Genetics, Perceive Bio, and Amber Bio, each dedicated to advancing therapies targeting various retinal conditions. Opus Genetics, for instance, received $7 million to support its gene therapy initiatives for orphan inherited retinal disease indications, resulting in the dosing of the first patient in an LCA5 Phase I/II clinical trial in August 2023.
Additionally, a $2.6 million investment in Perceive Bio aims to develop a complement factor H gene therapy program for dry age-related macular degeneration (AMD) and an innovative approach for glaucoma and retinal diseases. Amber Bio received $1.8 million to advance its RNA editing platform, with applications targeting retinal degeneration among other conditions.
Through these strategic investments, the Foundation Fighting Blindness Retinal Degeneration Fund is making strides toward translating cutting-edge research into viable clinical therapies, ultimately offering hope and potential solutions to those affected by retinal degenerative diseases.
This information is meant to be a general summary of Foundation Fighting Blindness Retinal Degeneration Fund. Please take the time to review official sources before making any decisions based upon the content provided here.
Financials
This financial information is from Propublica.
Other financial information:
This information is from the most recently submitted tax form from this organization, which was in 2023.
- Investment Income: -$5,603,437
- Gross Receipts: $15,223,946
Assets and Liabilities:
- Total Assets: $47,303,067
- Total Liabilities: $65,457
- Net Assets: $47,237,610
Want to help this charity, for free? You can click here to learn more about Give Freely
Organization Details
Founding Year
2003
Phone
(410) 423-0600Principal Officer
Russell W Kelley
Main Address
6925 OAKLAND MILLS ROAD 701, COLUMBIA, MD, 21045
NTEE Category
Code: H11 - Medical research
If you are a representative of Foundation Fighting Blindness Retinal Degeneration Fund and wish to learn more about how Give Freely can help you raise funds, please click here: https://givefreely.com/nonprofits/. Our services are offered at no cost to your organization.